A Comparative Clinical Study of Latanoprost and Isopropyl Unoprostone in Japanese Patients with Primary Open-Angle Glaucoma and Ocular Hypertension

PurposeTo compare the efficacy and safety of latanoprost versus isopropyl unoprostone (unoprostone) in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH). MethodsAn 8-week, multicenter, randomized, comparative study was performed in 48 Japanese patients with POAG or OH. Four patients (two in each group) withdrew from the study, but their data were included in the safety assessment but not in the intraocular pressure (IOP) evaluation. The patients were randomly treated with latanoprost 0.005% once daily or unoprostone 0.12% twice daily for 8 weeks. IOP was measured at baseline and 2, 4, and 8 weeks after treatment. In addition, ocular and systemic adverse events were recorded. ResultsThe baseline IOPs were similar between the latanoprost (n = 25) and unoprostone (n = 19) groups (24.3 ± 2.4 mm Hg vs 23.3 ± 2.1 mm Hg, respectively, P = 0.18). The IOP reductions from baseline at 2, 4, and 8 weeks after treatment were 5.8 ± 2.4, 6.6 ± 2.5, and 6.7 ± 2.0 mm Hg in the latanoprost group, and 3.8 ± 2.0, 3.5 ± 2.3, and 3.3 ± 3.0 mm Hg in the unoprostone group, respectively. The IOP reduction in the latanoprost group at 8 weeks was larger than that in the unoprostone group (P < 0.001, analysis of covariance). Five adverse events were observed in 4 (15%) of 27 patients in the latanoprost group, and five adverse events were observed in 4 (20%) of 21 patients in the unoprostone group. There was no difference in the incidence of adverse events between groups (P = 0.71). ConclusionLatanoprost produced a statistically greater reduction in IOP than unoprostone in Japanese patients with POAG or OH.

[1]  Y. Chan,et al.  A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. , 2001, American journal of ophthalmology.

[2]  R. Susanna,et al.  A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. , 2001, Ophthalmology.

[3]  M. Yablonski,et al.  Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. , 1999, American journal of ophthalmology.

[4]  J. Rouland,et al.  A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension. , 1999, Current medical research and opinion.

[5]  W. C. Stewart,et al.  The Effects of Unoprostone Isopropyl 0.12% and Timolol Maleate 0.5% on Diurnal Intraocular Pressure , 1998, Journal of glaucoma.

[6]  M. Yablonski,et al.  Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow. , 1998, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[7]  R. Brubaker,et al.  Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. , 1997, Survey of ophthalmology.

[8]  H. Mishima,et al.  Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. , 1997, Survey of ophthalmology.

[9]  M. Araie,et al.  A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. , 1996, Archives of ophthalmology.

[10]  L. Bito,et al.  Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. , 1996, Archives of ophthalmology.

[11]  C. Camras.  Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. , 1996, Ophthalmology.

[12]  J. Stjernschantz,et al.  A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. , 1996, Ophthalmology.

[13]  A. Alm,et al.  Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. , 1995, Ophthalmology.

[14]  B. Sjöquist,et al.  Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2a analogue , 1995 .

[15]  Y. Goh,et al.  Pharmacological characterization of prostaglandin-related ocular hypotensive agents , 1994 .

[16]  M. Yablonski,et al.  Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes , 1993 .

[17]  M. Yablonski,et al.  Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. , 1993, Ophthalmology.

[18]  Y. Kitazawa,et al.  Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. , 1993, Japanese journal of ophthalmology.

[19]  M. Yablonski,et al.  Fluorophotometric study of epinephrine and timolol in human subjects. , 1981, Archives of ophthalmology.

[20]  R. Brubaker,et al.  Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. , 1980, Investigative ophthalmology & visual science.